GlassScriptPhysician profile
Franklin C H Lee
NPI 1184949588
$11,756.53
in general payments reported to CMS, 2019-2025
13 companies · $5,427 in 2025
The $5,427 reported for 2025 was more than what 91% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,191 · 2020: $288 · 2021: $1,013 · 2022: $1,201 · 2023: $1,469 · 2024: $1,168 · 2025: $5,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,688 · Travel and Lodging: $3,341 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,687.77 |
| Travel and Lodging | $3,340.76 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $5,918.67 | 2019-2025 | Rezum Generator, Lithovue, Lumenis Pulse 120h |
| Angiodynamics, INC. | $4,465.14 | 2024-2025 | Nanoknife |
| Olympus America INC. | $365.43 | 2022-2024 | Itind System, Uretero-Reno Videoscope, Bovie |
| Astellas Pharma US INC | $235.15 | 2019 | |
| Calyxo, INC. | $172.62 | 2025 | Cvac Aspiration System |
| Histosonics, INC. | $172.06 | 2025 | |
| Pfizer INC. | $125.00 | 2019 | |
| Smith+Nephew, INC. | $119.66 | 2020 | |
| Lumenis, INC | $77.73 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Ferring Pharmaceuticals INC. | $30.70 | 2025 | Adstiladrin |
| Urogen Pharma, INC. | $21.64 | 2024 | |
| Abbvie INC. | $17.67 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Franklin Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.